A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Severe and Critical COVID-19 Condition
Latest Information Update: 30 Aug 2024
At a glance
- Drugs UMSC 01 (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia
- Focus Therapeutic Use
- Sponsors Ever Supreme Bio Technology
- 28 Aug 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 28 Aug 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
- 17 Aug 2022 New trial record